Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Shuitirou Iwasaki"'
Autor:
Kuniyasu Irie, Makoto Kako, Kazushi Numata, Yusuke Saigusa, Katsuaki Ogushi, Tatehiro Kagawa, Yusuke Sano, Shin Maeda, Manabu Morimoto, Takahide Nakazawa, Tomoaki Fujikawa, Masako Shomura, Hisashi Hidaka, Shogo Iwabuchi, Makoto Ueno, Shunji Hirose, Nobuhiro Hattori, Kota Tsuruya, Yosuke Kunishi, Taito Fukushima, Shuitirou Iwasaki, Makoto Chuma, Satoshi Kobayashi, Haruki Uojima, Tsunamasa Watanabe, Naohisa Wada, Katsuaki Tanaka, Kotaro Matsunaga, Kuniyuki Kawano
Publikováno v:
Clinical and Experimental Gastroenterology, Vol Volume 13, Pp 385-396 (2020)
Clinical and Experimental Gastroenterology
Clinical and Experimental Gastroenterology
Katsuaki Ogushi,1,* Makoto Chuma,1,* Haruki Uojima,2 Hisashi Hidaka,2 Kazushi Numata,1 Satoshi Kobayashi,3 Shunji Hirose,4 Nobuhiro Hattori,5 Tomoaki Fujikawa,6 Takahide Nakazawa,2 Naohisa Wada,2 Shuitirou Iwasaki,2 Taito Fukushima,3 Yusuke Sano,3 Ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3618264471d6d089411ec4e3f7a280ab
https://www.dovepress.com/safety-and-efcacy-of-lenvatinib-treatment-in-childndashpugh-a-and-b-pa-peer-reviewed-article-CEG
https://www.dovepress.com/safety-and-efcacy-of-lenvatinib-treatment-in-childndashpugh-a-and-b-pa-peer-reviewed-article-CEG
Autor:
Yoshimasa Shimma, Shigeru Iwase, Ehira Takuya, Chikako Tokoro, Nobuhiro Hattori, Tatehiro Kagawa, Yuki Miura, Yoshitaka Arase, Kota Tsuruya, Taito Fukushima, Manabu Morimoto, Chika Kusano, Ikeda Hiroki, Makoto Ueno, Shuitirou Iwasaki, Makoto Chuma, Shunji Hirose, Hisashi Hidaka, Haruki Uojima, Kazushi Numata, Shin Maeda, Shun Tezuka, Satoshi Moriya, Tsunamasa Watanabe, Naohisa Wada, Kousuke Kubota, Satoshi Kobayashi
Publikováno v:
Hepatology research : the official journal of the Japan Society of HepatologyREFERENCES. 52(3)
Purpose To assess the impact of clinical factors on the safety and efficacy of atezolizumab plus bevacizumab (ATZ+BV) treatment in patients with unresectable hepatocellular carcinoma (u-HCC). Method Ninety-four u-HCC patients who were treated with A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2c06911e400124e16ed553cfe50b0b2
https://pubmed.ncbi.nlm.nih.gov/34761470
https://pubmed.ncbi.nlm.nih.gov/34761470
Autor:
Toshifumi Tada, Nobuhiro Hattori, Shinya Fukunishi, S Iwabuchi, Haruki Uojima, Makoto Ueno, Hisashi Hidaka, Shunji Hirose, Kazuhiro Nouso, Hideko Ohama, Tatehiro Kagawa, Kazuto Tajiri, Satoshi Yasuda, Michiie Sakamoto, Toru Ishikawa, Joji Tani, Satoshi Moriya, Atsushi Hiraoka, Naohisa Wada, Shinichiro Nakamura, Tsunamasa Watanabe, Masanori Atsukawa, Hiroshi Shibata, Manabu Morimoto, Takashi Kumada, Norio Itokawa, Makoto Chuma, Taito Fukushima, Kazuya Kariyama, Satoshi Kobayashi, Hidenori Toyoda, Ei Itobayashi, Shuitirou Iwasaki, Michitaka Imai, Shin Maeda, Kazushi Numata
Publikováno v:
Hepatology research : the official journal of the Japan Society of HepatologyReferences. 51(2)
Aims To assess the safety, efficacy, and prognostic impact of clinical factors associated with lenvatinib treatment in highly advanced hepatocellular carcinoma (HCC) with tumor thrombus in the main portal vein trunk (VP4) or tumor with more than 50%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1bb253cc2174d86c94dfc94ffc84941
https://pubmed.ncbi.nlm.nih.gov/33270323
https://pubmed.ncbi.nlm.nih.gov/33270323
Autor:
Naohisa Wada, Nobuhiro Hattori, Masanori Atsukawa, Hisashi Hidaka, Kazushi Numata, Manabu Morimoto, Akito Nozaki, Haruki Uojima, Takashi Kumada, Tatehiro Kagawa, Hiroyuki Fukuda, Atsushi Hiraoka, Taeang Arai, Makoto Chuma, Shuitirou Iwasaki, Katsuaki Ogushi, Shin Maeda, Hidenori Toyoda, Yuki Miura, Norio Itokawa, Takahide Nakazawa, Toshifumi Tada, Kojiro Michitaka, Shunji Hirose, Makoto Kako, Shuhei Nishigori, Satoshi Hishiki
Publikováno v:
Cancers
Volume 12
Issue 2
Cancers, Vol 12, Iss 2, p 293 (2020)
Volume 12
Issue 2
Cancers, Vol 12, Iss 2, p 293 (2020)
Predictive biomarkers of the response of hepatocellular carcinoma (HCC) to Lenvatinib therapy have not yet been clarified. The aim of this study was to identify clinically significant biomarkers of response to Lenvatinib therapy, to target strategies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03971838a7937b4920ef802ebe34f7c3